相关实验视频

Updated: Jun 13, 2025

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

对抑制EphA2的计算见解:集成基于结构的虚拟选,对接和分子动力学模拟,用于小分子发现

Mohd Nehal¹, Jahanarah Khatoon², Salman Akhtar³

¹Department of Biosciences, Integral University, Lucknow, 226026, Uttar Pradesh, India. mnehal@student.iul.ac.in.

Cellular and molecular biology (Noisy-le-Grand, France)

|September 12, 2024

概括

研究人员发现了针对EphA2的新型小分子,这是与癌症有关的蛋白质. 这些化合物表现出强大的结合亲和力和稳定性,在癌症治疗中具有选择性EphA2抑制的潜力.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
计算化学计算化学

背景情况:

埃弗林A型受体-2 (EphA2) 在各种癌症中经常过度表达和功能障碍,与疾病进展和不良预后相关.
用小分子抑制剂向EphA2是一个有希望的治疗策略,可以抵消癌症的发展和转移.

研究的目的:

通过基于结构的虚拟查来识别新型,强效和选择性的EphA2小分子抑制剂.
通过分子对接和模拟来评估候选抑制剂的结合亲和力和稳定性.

主要方法:

使用Mcule数据库和药物相似性过器进行了基于结构的虚拟查 (SBVS).
化合物经过毒性和ADME标准的过,随后使用Mcule单点击,DockThor和SwissDock进行多得分对接评估.
对包括达沙替尼在内的排名第一的化合物进行了分子动力学 (MD) 模拟,以分析稳定性和结合的自由能量.

主要成果:

虚拟查发现了几种强效的EphA2抑制剂,其中四种新型小分子 (Mcule-1579910267,Mcule-1893218381,Mcule-3981378344,Mcule-8617639093) 具有与已知抑制剂dasatinib相比或超过的结合亲缘关系.
在MD模拟中,Mcule-8617639093表现出显著的稳定性,由RMSD,RMSF,SASA,ΔGsolv和Rg分析表明.
已识别的化合物显示强大的结合自由能量 (ΔG) 值,新型分子达到高达-9.3 kcal/mol.

结论:

新型的小分子,特别是Mcule-8617639093,对EphA2表现出强大而稳定的结合,表明它们作为选择性抑制剂的潜力.
这些发现为开发新向治疗针对EphA2驱动的癌症提供了坚实的基础.

更多相关视频

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Protein-protein Interfaces

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...